CYTK Stock Analysis: Cytokinetics | NASDAQ

Cardiac Myosin Inhibitors, Heart Failure Drugs, Muscle Activators, HCM Treatments

Total Rating 19

Safety 33

Buy Signal -0.66

Biotechnology
Industry Rotation: -4.2

Market Cap: 8.61B
Avg Turnover: 125M

Risk 3d forecast

Volatility49.3%

VaR 5^th Pctl7.46%

VaR vs Median-6.92%

Reward TTM

Sharpe Ratio0.32

Rel. Str. IBD24

Rel. Str. Peer Group31.8 pctl

Character TTM

Beta0.936

Beta Downside0.683

Hurst Exponent0.468

Choppyness29.7%

Drawdowns 3y

Max DD72.39%

CAGR/Max DD0.34

CAGR/Mean DD0.57

EPS (Earnings per Share)

Last SUE: 0.72
Qual. Beats: 0

Revenue

Rev. CAGR: 286.45%
Rev. Trend: 85.6%

Last SUE: 0.64
Qual. Beats: 0

Warnings

Negative Equity With Losses

Interest Coverage Ratio Critical

Beneish M-Score Likely Earnings Manipulation

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan -7.7% 21

Feb -4.3% 45

Mar -1.6% 22

Apr +7.1% 41

May -2.6% 8

Jun -0.2% 5

Jul +3.2% 20

Aug +2.1% 29

Sep -9.5% 42

Oct -6.5% 25

Nov +0.2% 2

Dec -0.3% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CYTK Cytokinetics

Cytokinetics, Incorporated (NASDAQ: CYTK) is a U.S.-based biopharmaceutical company founded in 1997 and headquartered in South San Francisco, California. The company specializes in discovering, developing, and commercializing novel small molecule therapeutics that target muscle contractility, including both muscle activators and inhibitors, aimed at treating debilitating diseases.

The companys commercial product, MYQORZO, is an oral cardiac myosin inhibitor approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its pipeline includes Aficamten, a cardiac myosin inhibitor in development for hypertrophic cardiomyopathy, and omecamtiv mecarbil, a potential treatment for heart failure with severely reduced ejection fraction. Earlier-stage candidates include Ulacamten (Phase 1) for heart failure with preserved ejection fraction and CK-089 (Phase 1), a fast skeletal muscle troponin activator.

As a mid-cap biotechnology company, Cytokinetics operates within a sector characterized by lengthy and capital-intensive drug development cycles, reliance on intellectual property protection, and revenue heavily dependent on regulatory approvals and successful commercialization. The company went public in 2004 and primarily generates income through product sales supplemented by collaboration and licensing arrangements common across the biopharmaceutical industry.

Headlines to Watch Out For

MYQORZO launch revenue accelerates in oHCM market
Aficamten Phase 3 data drives regulatory submission timeline
Omecamtiv mecarbil approval expands heart failure treatment portfolio

Piotroski VR-10 (Strict) 1.0

Net Income: -894.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.40 > 0.02 and ΔFCF/TA 0.93 > 1.0
NWC/Revenue: 1.45k% < 20% (prev 881.1%; Δ 566.2% < -1%)
CFO/TA -0.29 > 3% & CFO -555.5m > Net Income -894.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.66 > 1.5 & < 3
Outstanding Shares: last quarter (132.1m) vs 12m ago 10.57% < -2%
Gross Margin: 84.97% > 18% (prev -227.0%; Δ 312.0% > 0.5%)
Asset Turnover: 4.51% > 50% (prev 7.00%; Δ -2.49% > 0%)
Interest Coverage Ratio: -6.68 > 6 (EBIT TTM -834.3m / Interest Expense TTM 124.8m)

Altman Z'' -6.74

A: 0.53 (Total Current Assets 1.21b - Total Current Liabilities 181.4m) / Total Assets 1.92b
B: -2.02 (Retained Earnings -3.89b / Total Assets 1.92b)
C: -0.53 (EBIT TTM -834.3m / Avg Total Assets 1.58b)
D: -0.08 (Book Value of Equity -173.5m / Total Liabilities 2.10b)
Altman-Z'' = -6.74 = D

Beneish M -1.01

DSRI: 3.0 (Receivables 24.4m/8.41m, Revenue 71.0m/85.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.86 (AQ_t 0.29 / AQ_t-1 0.16)
SGI: 0.83 (Revenue 71.0m / 85.7m)
TATA: -0.18 (NI -894.0m - CFO -555.5m) / TA 1.92b)
Beneish M = -1.01 (Cap -4..+1) = D

What is the price of CYTK shares?

As of October 22, 2026, the stock is trading at USD 62.86 with a total of 1,080,526 shares traded. Over the past week, the price has changed by +3.78%, over one month by -5.34%, over three months by -19.16% and over the past year by +7.75%.

Current recommended Stop Loss: 57.60 (which is 8.4% or 2.4 ATR below the current price).

Is CYTK a buy, sell or hold?

Cytokinetics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CYTK.

StrongBuy: 13
Buy: 7
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CYTK price?

Analysts Target Price	109.4	74%

Cytokinetics (CYTK) - Fundamental Data Overview as of 19 October 2026

Market Cap USD = 8.61b (8.61b USD * 1.0 USD.USD)
P/E Forward = 117.6471
P/S = 127.2721
P/B = 60.3093
P/EG = -0.42
Revenue TTM = 71.0m USD
EBIT TTM = -834.3m USD
EBITDA TTM = -821.8m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 48.4m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 123.5m
Net Debt = 297.0m USD (calculated: Debt 1.39b - CCE 1.10b)
Enterprise Value = 8.91b USD (8.61b + Debt 1.39b - CCE 1.10b)
Interest Coverage Ratio = -6.68 (Ebit TTM -834.3m / Interest Expense TTM 124.8m)
EV/FCF = -11.43x (Enterprise Value 8.91b / FCF TTM -779.4m)
FCF Yield = -8.75% (FCF TTM -779.4m / Enterprise Value 8.91b)
FCF Margin = -1.10k% (FCF TTM -779.4m / Revenue TTM 71.0m)
Net Margin = -1.26k% (Net Income TTM -894.0m / Revenue TTM 71.0m)
Gross Margin = 84.97% ((Revenue TTM 71.0m - Cost of Revenue TTM 10.7m) / Revenue TTM)
Gross Margin QoQ = 91.44% (prev 87.64%)
Tobins Q-Ratio = 4.63 (Enterprise Value 8.91b / Total Assets 1.92b)
Interest Expense / Debt = 8.95% (Interest Expense 124.8m / Debt 1.39b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -659.1m (EBIT -834.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.98 (Total Current Assets 1.21b / Total Current Liabilities 201.9m)
Debt / Equity = -8.04 (negative equity) (Debt 1.39b / totalStockholderEquity, last quarter -173.5m)
Debt / EBITDA = -0.36 (negative EBITDA) (Net Debt 297.0m / EBITDA -821.8m)
Debt / FCF = -0.38 (negative FCF - burning cash) (Net Debt 297.0m / FCF TTM -779.4m)
Total Stockholder Equity = -545.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.76% (Net Income -894.0m / Total Assets 1.92b)
RoE = 164.0% (negative equity) (Net Income TTM -894.0m / Total Stockholder Equity -545.2m)
RoCE = -145.2% (out of range, set to none) (EBIT -834.3m / Capital Employed (Equity -545.2m + L.T.Debt 1.12b))
RoIC = -36.86% (negative operating profit) (NOPAT -659.1m / Invested Capital 1.79b)
WACC = 8.54% (E(8.61b)/V(10.0b) * Re(8.78%) + D(1.39b)/V(10.0b) * Rd(8.95%) * (1-Tc(0.21)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.93 | Cagr: 12.21%
[DCF] Fair Price = unknown (Cash Flow -779.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.72 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 286.5% | SUE: 0.64 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.41 | Chg30d=+1.15% | Revisions=+25% | Analysts=17
EPS current Year (2026-12-31): EPS=-5.88 | Chg30d=+1.10% | Revisions=+25% | GrowthEPS=+10.1% | GrowthRev=+72.6%
EPS next Year (2027-12-31): EPS=-4.46 | Chg30d=-0.29% | Revisions=+25% | GrowthEPS=+24.1% | GrowthRev=+181.1%
[Analyst] Revisions Ratio: +50% (up=3, down=0)